A blockbuster cancer drug? TYK’s claims go under the microscope 頭對頭試驗勝過“肺癌藥王”？同源康醫藥臨床結果引爭議
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme 同源康醫藥公布重大利好消息后的第一個交易日，也是該股被納入港股通名單生效的第一天。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.